Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Conditions
Interventions
INCB099280
adagrasib
Locations
14
United States
Valkyrie Clinical Trials
Los Angeles, California, United States
Banner Md Anderson Cancer Center
Greeley, Colorado, United States
Henry Ford Health System
Detroit, Michigan, United States
Mary Crowley Cancer Research Centers McCrc Headquarters
Dallas, Texas, United States
Inova Schar Cancer Institute
Falls Church, Virginia, United States
Fondazione Del Piemonte Per L Oncologia Ircc Candiolo
Candiolo, Italy
Start Date
December 28, 2023
Primary Completion Date
April 11, 2025
Completion Date
July 11, 2025
Last Updated
August 3, 2025
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Incyte Corporation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions